Revenue increased 5.6%
Revenue changed +5.6% from the comparable as-filed period.
$186.9M→$197.3M3 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed +5.6% from the comparable as-filed period.
SBC / revenue changed -89 basis points from the comparable as-filed period.
Stock-based compensation changed -15.9% from the comparable as-filed period.
Research & development changed -2.2% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.